Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?

References

• DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64:252-71; PMID:24890451; http://dx.doi.org/10.3322/caac.21235
   PubMed Web of Science ®Google Scholar
• Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am College Cardiol 2014; 64:938-45; PMID:25169180; http://dx.doi.org/10.1016/j.jacc.2014.06.1167
   PubMed Web of Science ®Google Scholar
• Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Failure 2011; 13:1-10; PMID:21169385; http://dx.doi.org/10.1093/eurjhf/hfq213
   PubMed Web of Science ®Google Scholar
• Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008; 31:459-67; PMID:18484781; http://dx.doi.org/10.2165/00002018-200831060-00002
   PubMed Web of Science ®Google Scholar
• Tocchetti CG, Carpi A, Coppola C, Quintavalle C, Rea D, Campesan M, Arcari A, Piscopo G, Cipresso C, Monti MG, et al. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. Eur J Heart Failure 2014; 16:358-66; PMID:24464789; http://dx.doi.org/10.1002/ejhf.50
   PubMed Web of Science ®Google Scholar
• Stebbing J, Copson E, O'Reilly S. Herceptin (trastuzamab) in advanced breast cancer. Cancer Treatment Rev 2000; 26:287-90; PMID:10913383; http://dx.doi.org/10.1053/ctrv.2000.0182
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med 2001; 344:783-92; PMID:11248153; http://dx.doi.org/10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Eng J Med 2005; 353:1673-84; PMID:16236738; http://dx.doi.org/10.1056/NEJMoa052122
   PubMed Web of Science ®Google Scholar
• Tocchetti CG, Ragone G, Coppola C, Rea D, Piscopo G, Scala S, De Lorenzo C, Iaffaioli RV, Arra C, Maurea N. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur J Heart Failure 2012; 14:130-7; PMID:22219501; http://dx.doi.org/10.1093/eurjhf/hfr165
   PubMed Web of Science ®Google Scholar
• Maurea N, Coppola C, Ragone G, Frasci G, Bonelli A, Romano C, Iaffaioli RV. Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. J Cardiovascular Med 2010; 11:861-8; PMID:20072001; http://dx.doi.org/10.2459/JCM.0b013e328336b4c1
   PubMed Web of Science ®Google Scholar
• Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 2001; 28:20-7; PMID:11301371; http://dx.doi.org/10.1016/S0093-7754(01)90189-7
   PubMed Web of Science ®Google Scholar
• De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circulation Res 2010; 106:35-46; PMID:20056944; http://dx.doi.org/10.1161/CIRCRESAHA.109.205906
   PubMed Web of Science ®Google Scholar
• Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012; 104:1293-305; PMID:22949432; http://dx.doi.org/10.1093/jnci/djs317
   PubMed Web of Science ®Google Scholar
• Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am College Cardiol 2012; 60:2504-12; PMID:23158536; http://dx.doi.org/10.1016/j.jacc.2012.07.068
   PubMed Web of Science ®Google Scholar
• Serrano C, Cortes J, De Mattos-Arruda L, Bellet M, Gomez P, Saura C, Perez J, Vidal M, Munoz-Couselo E, Carreras MJ, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Annals Oncol 2012; 23:897-902; PMID:21828361; http://dx.doi.org/10.1093/annonc/mdr348
   PubMed Web of Science ®Google Scholar
• Oliva S, Cioffi G, Frattini S, Simoncini EL, Faggiano P, Boccardi L, Pulignano G, Fioretti AM, Giotta F, Lestuzzi C, et al. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world? Oncologist 2012; 17:917-24; PMID:22673631; http://dx.doi.org/10.1634/theoncologist.2011-0445
   PubMed Web of Science ®Google Scholar
• Russo G, Cioffi G, Gori S, Tuccia F, Boccardi L, Khoury G, Lestuzzi C, Maurea N, Oliva S, Faggiano P, et al. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. J Cardiovascular Med 2014; 15:141-6; PMID:24534802; http://dx.doi.org/10.2459/JCM.0b013e328365afb5
   PubMed Web of Science ®Google Scholar
• Fedele C, Riccio G, Malara AE, D'Alessio G, De Lorenzo C. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Res Treatment 2012; 134:595-602; PMID:22674190; http://dx.doi.org/10.1007/s10549-012-2103-8
   PubMed Web of Science ®Google Scholar
• Bersell K, Arab S, Haring B, Kuhn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009; 138:257-70; PMID:19632177; http://dx.doi.org/10.1016/j.cell.2009.04.060
   PubMed Web of Science ®Google Scholar
• ElZarrad MK, Mukhopadhyay P, Mohan N, Hao E, Dokmanovic M, Hirsch DS, Shen Y, Pacher P, Wu WJ. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PloS One 2013; 8:e79543; PMID:24255707; http://dx.doi.org/10.1371/journal.pone.0079543
   PubMed Web of Science ®Google Scholar
• Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, Laccetti P, Hrelia S, D'Alessio G, De Lorenzo C. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. Faseb J 2009; 23:3171-8; PMID:19417081; http://dx.doi.org/10.1096/fj.09-131383
   PubMed Web of Science ®Google Scholar
• Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circulation Cardiovascular Imaging 2012; 5:596-603; PMID:22744937; http://dx.doi.org/10.1161/CIRCIMAGING.112.973321
   PubMed Web of Science ®Google Scholar
• Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Association 2014; 3:e000472; PMID:24584736; http://dx.doi.org/10.1161/JAHA.113.000472
   PubMed Web of Science ®Google Scholar
• Magnano LC, Martinez Cibrian N, Andrade Gonzalez X, Bosch X. Cardiac complications of chemotherapy: role of prevention. Curr Treatment Options Cardiovascular Med 2014; 16:312; PMID:24817319; http://dx.doi.org/10.1007/s11936-014-0312-7
   PubMedGoogle Scholar
• Tarantini L, Gori S, Faggiano P, Pulignano G, Simoncini E, Tuccia F, Ceccherini R, Bovelli D, Lestuzzi C, Cioffi G, et al. Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Annals Oncol 2012; 23:3058-63; http://dx.doi.org/10.1093/annonc/mds127
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7:332-44; PMID:17457301; http://dx.doi.org/10.1038/nrc2106
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhou M. Neuregulin signaling and heart failure. Curr Heart Failure Reports 2010; 7:42-7
   Google Scholar
• Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 2007; 116:954-60; PMID:17709650; http://dx.doi.org/10.1161/CIRCULATIONAHA.107.690487
   PubMed Web of Science ®Google Scholar
• Sysa-Shah P, Xu Y, Guo X, Belmonte F, Kang B, Bedja D, Pin S, Tsuchiya N, Gabrielson K. Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice. PloS One 2012; 7:e42805; PMID:22912742; http://dx.doi.org/10.1371/journal.pone.0042805
   PubMedGoogle Scholar
• Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, Naik TJ, Prasad SV, Ardehali H. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 2009; 284:2080-7; PMID:19017630; http://dx.doi.org/10.1074/jbc.M804570200
   PubMed Web of Science ®Google Scholar
• Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ, Rosenzweig A. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am College Cardiol 2004; 44:2231-8; PMID:15582322; http://dx.doi.org/10.1016/j.jacc.2004.08.066
   PubMed Web of Science ®Google Scholar
• Chien KR. Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin Oncol 2000; 27:9-14; discussion 92-100; PMID:11236034
   PubMed Web of Science ®Google Scholar
• Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010; 7:564-75; PMID:20842180; http://dx.doi.org/10.1038/nrcardio.2010.121
   PubMed Web of Science ®Google Scholar
• Albini A, Cesana E, Donatelli F, Cammarota R, Bucci EO, Baravelli M, Anza C, Noonan DM. Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Fut Cardiol 2011; 7:693-704; PMID:21929348; http://dx.doi.org/10.2217/fca.11.54
   PubMedGoogle Scholar
• Zeglinski M, Ludke A, Jassal DS, Singal PK. Trastuzumab-inducn health and disease. Physiol Rev 2007; 87:315-424
   PubMed Web of Science ®Google Scholar
• Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87:315-424
   PubMed Web of Science ®Google Scholar
• Jassal DS, Han SY, Hans C, Sharma A, Fang T, Ahmadie R, Lytwyn M, Walker JR, Bhalla RS, Czarnecki A, et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Society Echocardiography 2009; 22:418-24; PMID:19269133; http://dx.doi.org/10.1016/j.echo.2009.01.016
   PubMed Web of Science ®Google Scholar
• Walker JR, Sharma A, Lytwyn M, Bohonis S, Thliveris J, Singal PK, Jassal DS. The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity. J Am Society Echocardiography 2011; 24:699-705; PMID:21353471http://dx.doi.org/10.1016/j.echo.2011.01.018
   PubMed Web of Science ®Google Scholar
• Fedele C, Riccio G, Coppola C, Barbieri A, Monti MG, Arra C, Tocchetti CG, D'Alessio G, Maurea N, De Lorenzo C. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res Treatment 2012; 133:511-21; PMID:21947749; http://dx.doi.org/10.1007/s10549-011-1783-9
   PubMed Web of Science ®Google Scholar
• Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983; 43:460-72; PMID:6293697
   PubMed Web of Science ®Google Scholar
• Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Eng J Med 1998; 339:900-5; PMID:9744975; http://dx.doi.org/10.1056/NEJM199809243391307
   PubMed Web of Science ®Google Scholar
• Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 1996; 98:1253-60; PMID:8787689; http://dx.doi.org/10.1172/JCI118909
   PubMed Web of Science ®Google Scholar
• Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226:466-8; PMID:6093249; http://dx.doi.org/10.1126/science.6093249
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012; 18:1639-42; PMID:23104132; http://dx.doi.org/10.1038/nm.2919
   PubMed Web of Science ®Google Scholar
• Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 2002; 62:4592-8; PMID:12183413
   PubMed Web of Science ®Google Scholar
• Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, Lestuzzi C, Maurea N, Oliva S, Russo G, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Cardiac Failure 2012; 18:113-9; http://dx.doi.org/10.1016/j.cardfail.2011.10.015
   PubMed Web of Science ®Google Scholar
• Wells QS, Lenihan DJ. Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected? Progress Cardiovascular Dis 2010; 53:140-8; PMID:20728701; http://dx.doi.org/10.1016/j.pcad.2010.06.005
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano, G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131:1981-8; PMID:25948538; http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013777
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Eng J Med 2005; 353:1659-72; PMID:16236737; http://dx.doi.org/10.1056/NEJMoa052306
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Eng J Med 2011; 365:1273-83; PMID:21991949; http://dx.doi.org/10.1056/NEJMoa0910383
   PubMed Web of Science ®Google Scholar
• Valachis A, Nearchou A, Polyzos NP, Lind P. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. Int J Cancer J Int Du Cancer 2013; 133:2245-52; PMID:23629633; http://dx.doi.org/10.1002/ijc.28234
   PubMed Web of Science ®Google Scholar
• Tocchetti CG, Gallucci G, Coppola C, Piscopo G, Cipresso C, Maurea C, Giudice A, Iaffaioli RV, Arra C, Maurea N. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Failure 2013; 15:482-9; PMID:23325019; http://dx.doi.org/10.1093/eurjhf/hft008
   PubMed Web of Science ®Google Scholar